Literature DB >> 29133602

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.

Subodh Verma1, C David Mazer2, Mohammed Al-Omran3,4, Silvio E Inzucchi5, David Fitchett6, Uwe Hehnke7, Jyothis T George7, Bernard Zinman8,9.   

Abstract

Entities:  

Keywords:  diabetes mellitus peripheral arterial disease; sodium-glucose cotransporter 2

Mesh：

Substances：

Year:  2017        PMID： 29133602     DOI： 10.1161/CIRCULATIONAHA.117.032031

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  35 in total

Review 1.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 2.  Empagliflozin: A Review in Type 2 Diabetes.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

3.  Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Authors:  Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

4.  Diabetes: Further insights into SGLT2 inhibitors.

Authors:  Irene Fernández-Ruiz
Journal:  Nat Rev Cardiol       Date:  2017-11-30       Impact factor: 32.419

5.  The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.

Authors:  Ketan Dhatariya; Stephen C Bain; John B Buse; Richard Simpson; Lise Tarnow; Margit Staum Kaltoft; Michael Stellfeld; Karen Tornøe; Richard E Pratley
Journal:  Diabetes Care       Date:  2018-08-02       Impact factor: 19.112

Review 6.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

7.  [Principles of angiology in lower extremity arterial disease (LEAD)].

Authors:  Christine Espinola-Klein
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

8.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; James L Januzzi; Rita R Kalyani; Mikhail Kosiborod; Melissa Magwire; Pamela B Morris; Joshua J Neumiller; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2020-08-05       Impact factor: 24.094

Review 9.  Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Authors:  Volker Vallon; Subodh Verma
Journal:  Annu Rev Physiol       Date:  2020-11-16       Impact factor: 19.318

10.  Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes.

Authors:  Margaret Nalugo; Nikolai Harroun; Chenglong Li; Larisa Belaygorod; Clay F Semenkovich; Mohamed A Zayed
Journal:  Vasc Med       Date:  2020-10-23       Impact factor: 3.239
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.